Biology of Blood and Marrow Transplantation
Volume 15, Issue 5 , Pages 610-617 , May 2009

Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes

  • Koen Van Besien

      Affiliations

    • Section of Hematology/Oncology, University of Chicago, Chicago, Illinois
    • Corresponding Author InformationCorrespondence and reprint requests to: Koen Van Besien, MD, Section of Hematology/Oncology, University of Chicago, 5841 South Maryland Avenue, Room 1 209, Chicago, IL 60637.
    • ,
  • Rangesh Kunavakkam

      Affiliations

    • The Department of Health Studies, University of Chicago, Chicago, Illinois
    • ,
  • Gaby Rondon

      Affiliations

    • Department of Blood and Marrow Transplantation, M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Marcos De Lima

      Affiliations

    • Department of Blood and Marrow Transplantation, M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Andrew Artz

      Affiliations

    • Section of Hematology/Oncology, University of Chicago, Chicago, Illinois
    • ,
  • Betul Oran

      Affiliations

    • Department of Blood and Marrow Transplantation, M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Sergio Giralt

      Affiliations

    • Department of Blood and Marrow Transplantation, M.D. Anderson Cancer Center, Houston, Texas

Received 19 October 2008 ,Accepted 27 January 2009.

 Financial disclosure: See Acknowledgments on page 616.

PII: S1083-8791(09)00073-1

doi: 10.1016/j.bbmt.2009.01.021

Biology of Blood and Marrow Transplantation
Volume 15, Issue 5 , Pages 610-617 , May 2009

Article Tools

* Image Usage & Resolution